BMTCN COMPREHENSIVE EXAM STUDY
GUIDE WITH COMPLETE SOLUTIONS
●● Therapies associated with therapy-related acute leukemia and MDS
Answer: alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan,
ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide,
mitoxantrone)
●● Genetic predispositions that increase risk of primary and secondary
cancers
Answer: neurofibromatosis type 1, Fanconi anemia
●● Risk factors for PTLD
Answer: T-cell depleted graft, mismatched related or unrelated donor.
Busulfan, ATG, mAbs, TBI
patient w/ primary immunodeficiency, acute or extensive GVHD, EBV
●● Risk factors for secondary solid tumors
Answer: younger age at HSCT, TBI, chronic GVHD, increasing time
from transplant, infections, genetic predisposition, lifestyle factors
●● Treatment options for PTLD
, Answer: EBV-specific cytotoxic T cells, mAbs targeted to B cells
(rituximab), combination chemotherapy
●● Treatment options for secondary MDS/acute leukemia
Answer: conventional chemo or allo transplant. Poor outcomes.
●● QOL domains
Answer: Physical, Functional, Psychological, Social,
Spiritual/existential, Multiple interactions between domains
●● Altered sexual health in male HSCT survivors
Answer: damage to the hypothalamic-pituitary-gonadal axis: elevated
FSH, elevated LH, low testosterone levels; cavernosal arterial
insufficiency causing ED
●● Altered sexual health in female HSCT survivors
Answer: alkylating agents and radiation cause infertility and premature
ovarian failure, elevated FSH and LG, low estradiol, menopausal
symptoms
●● Risk factors for vaginal alterations post transplant
Answer: POF (premature ovarian failure), TBI, chronic GVHD
●● Risk factors for infertility
GUIDE WITH COMPLETE SOLUTIONS
●● Therapies associated with therapy-related acute leukemia and MDS
Answer: alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan,
ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide,
mitoxantrone)
●● Genetic predispositions that increase risk of primary and secondary
cancers
Answer: neurofibromatosis type 1, Fanconi anemia
●● Risk factors for PTLD
Answer: T-cell depleted graft, mismatched related or unrelated donor.
Busulfan, ATG, mAbs, TBI
patient w/ primary immunodeficiency, acute or extensive GVHD, EBV
●● Risk factors for secondary solid tumors
Answer: younger age at HSCT, TBI, chronic GVHD, increasing time
from transplant, infections, genetic predisposition, lifestyle factors
●● Treatment options for PTLD
, Answer: EBV-specific cytotoxic T cells, mAbs targeted to B cells
(rituximab), combination chemotherapy
●● Treatment options for secondary MDS/acute leukemia
Answer: conventional chemo or allo transplant. Poor outcomes.
●● QOL domains
Answer: Physical, Functional, Psychological, Social,
Spiritual/existential, Multiple interactions between domains
●● Altered sexual health in male HSCT survivors
Answer: damage to the hypothalamic-pituitary-gonadal axis: elevated
FSH, elevated LH, low testosterone levels; cavernosal arterial
insufficiency causing ED
●● Altered sexual health in female HSCT survivors
Answer: alkylating agents and radiation cause infertility and premature
ovarian failure, elevated FSH and LG, low estradiol, menopausal
symptoms
●● Risk factors for vaginal alterations post transplant
Answer: POF (premature ovarian failure), TBI, chronic GVHD
●● Risk factors for infertility
